Cluster sell at Replimune Group, Inc.: six insiders sell $2.29M of REPL
Open-market sales between Nov 2 and Nov 16, none marked as part of a 10b5-1 plan. By the Insider Stock Trader: Alerts app. Information only, not investment advice.
Form 4 filings show six Replimune Group, Inc. insiders selling stock between Nov 2 and Nov 16, for a total of $2.29 million.
The largest sale came from Sushil Patel, a CEO, who sold 49,026 shares for $1.06 million. None of these filings marks the sale as made under a Rule 10b5-1 trading plan.
Konstantinos Xynos (chief medical officer) is the latest to report, in a filing on Nov 18. The table below lists who sold, when, and at what price.
Details from the SEC filing:
| Insider | Role | Trade date | Shares | Avg. price | Value | Filing |
|---|---|---|---|---|---|---|
| Kapil Dhingra | Director | Nov 2 | 21,500 | $19.00 | $408,500 | App · SEC |
| Joseph P Slattery | Director | Nov 9 | 5,200 | $21.80 | $113,360 | App · SEC |
| Emily Luisa Hill | CFO | Nov 16 | 14,709 | $21.60 | $317,714 | App · SEC |
| Sushil Patel | CEO | Nov 16 | 49,026 | $21.60 | $1,058,962 | App · SEC |
| Andrew Schwendenman | Chief Accounting Officer | Nov 16 | 2,148 | $21.60 | $46,397 | App · SEC |
| Konstantinos Xynos | Chief Medical Officer | Nov 16 | 16,198 | $21.60 | $349,877 | App · SEC |
| Total | $2,294,810 |
See every insider trade at Replimune Group, Inc.
Each row of the table links to its Form 4 on SEC.gov.
See all the latest insider trades · See earlier insider stories on Replimune Group, Inc.
Source: SEC Form 4. Information only, not investment advice. Not affiliated with or endorsed by the U.S. Securities and Exchange Commission.